New York, NY and Tel Aviv, ISRAEL, September 27, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — All Medical, Ltd. TOMDF, a comprehensive medical diagnostics and related solutions company, announced today that its majority-owned joint venture 3CL Pharma Ltd. received a USPTO-issued notification of approval for its proprietary SARS-CoV-2 3CL protease (major protease, Mpro, Nsp5). diagnostic TolloTest™ designed to detect and quantify the presence of 3CL protease in human tissue samples. Initially validated in upper respiratory tract (swab) specimens, TolloTest can provide PCR-like accuracy with similar convenience to a rapid antigen test. The company previously announced this positive data on TolloTest in inpatient and outpatient facilities such as nursing homes and schools.

The test is designed to quantify 3CL protease, which is measured for correlation with infectivity and may be a key feature of the SARS-CoV-2 viral persistence pathology in Long COVID. TolloTest is a potential biomarker companion test for the Company’s 3CL protease inhibitor dietary supplement Tollovid and a companion diagnostic for Tollovir, its phase 2 compound for hospitalized COVID. TolloTest may be marketed as a rapid point-of-care test in single-use and bulk screening formats, as a single-use home test, and as a laboratory-developed test (LDT) for use in highly complex CLIA labs and mobile labs for patient monitoring .

“The tremendous work we have done in Israel in discovering and proving this 3CL protease disease mechanism will be used in the next steps towards expanding the widespread adoption of dietary supplements and drugs to reduce SARS-CoV-2 replication and downregulation of the immune system,” said Dr. Dorit Arad, Founder and Chief Technology Officer at 3CL Pharma.

“The US market is huge and urgently needs new types of diagnostics to measure various aspects of the SARS-CoV-2 virus, particularly in hospitalized patients and…